ASCO oncology conference: NewLink Genetics (NLNK) -6.3% despite patients enjoying improved...


ASCO oncology conference: NewLink Genetics (NLNK) -6.3% despite patients enjoying improved survival rates in a Phase II trial of the company's algenpantucel-L treatment for pancreatic cancer. NewLink Genetics has also disclosed positive results in early stage trials of two other drugs (I, II).

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs